Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Results of the First Prospective Multi-institutional Treatment Study in Children With Bilateral Wilms Tumor (AREN0534): A Report From the Children's Oncology Group

Ehrlich, Peter MD, MSC*; Chi, Yuen Y. PhD; Chintagumpala, Murali M. MD; Hoffer, Fred A. MD§; Perlman, Elizabeth J. MD; Kalapurakal, John A. MD||; Warwick, Ann MD**; Shamberger, Robert C. MD††; Khanna, Geetika MD‡‡; Hamilton, Tom E. MD††; Gow, Ken W. MD§§; Paulino, Arnold C. MD¶¶; Gratias, Eric J. MD||||; Mullen, Elizabeth A. MD††; Geller, James I. MD***; Grundy, Paul E. MD†††; Fernandez, Conrad V. MD‡‡‡; Ritchey, Michael L. MD§§§; Dome, James S. MD, PhD¶¶¶


Due to an author error, co-author Jeff Dome was misidentified in “Results of the First Prospective Multi-institutional Treatment Study in Children With Bilateral Wilms Tumor (AREN0534) A Report From the Children's Oncology Group” which published in the September 2017 issue of Annals of Surgery.

Annals of Surgery. 267(3):e64, March 2018.

doi: 10.1097/SLA.0000000000002356

Objective: The Children's Oncology Group study AREN0534 aimed to improve event-free survival (EFS) and overall survival (OS) while preserving renal tissue by intensifying preoperative chemotherapy, completing definitive surgery by 12 weeks from diagnosis, and modifying postoperative chemotherapy based on histologic response.

Background: No prospective therapeutic clinic trials in children with bilateral Wilms tumors (BWT) exist. Historical outcomes for this group were poor and often involved prolonged chemotherapy; on NWTS-5, 4-year EFS for all children with BWT was 56%.

Methods: Patients were enrolled and imaging studies were centrally reviewed to assess for bilateral renal lesions. They were treated with 3-drug induction chemotherapy (vincristine, dactinomycin, and doxorubicin) for 6 or 12 weeks based on radiographic response followed by surgery and further chemotherapy determined by histology. Radiation therapy was provided for postchemotherapy stage III and IV disease.

Results: One hundred eighty-nine of 208 patients were evaluable. Four-year EFS and OS were 82.1% (95% CI: 73.5%–90.8%) and 94.9% (95% CI: 90.1%–99.7%. Twenty-three patients relapsed and 7 had disease progression. After induction chemotherapy 163 of 189 (84.0%) underwent definitive surgical treatment in at least 1 kidney by 12 weeks and 39% retained parts of both kidneys. Surgical approaches included: unilateral total nephrectomy with contralateral partial nephrectomy (48%), bilateral partial nephrectomy (35%), unilateral total nephrectomy (10.5%), unilateral partial nephrectomy (4%), and bilateral total nephrectomies (2.5%).

Conclusion: This treatment approach including standardized 3-drug preoperative chemotherapy, surgical resection within 12 weeks of diagnosis and response and histology-based postoperative therapy improved EFS and OS and preservation of renal parenchyma compared with historical outcomes for children with BWT.

Supplemental Digital Content is available in the text

*Section of Pediatric Surgery CS Mott Children's Hospital, University of Michigan, Ann Arbor MI

COG Data Center, University of Florida, Gainesville, FL

Texas Children's Cancer Center at Baylor College of Medicine, Houston, TX

§Fred Hutchison Cancer Center, University of Washington, Seattle, WA

Ann and Robert H Lurie Children's Hospital, Chicago, IL

||Northwestern University, Chicago, IL

**Walter Reed National Military Medical Center, Washington DC

††Boston Children's Hospital and Dana Farber Cancer Center, Boston, MA

‡‡Washington University of St Louis, St Louis, MO

§§University of Washington, Seattle, WA

¶¶MD Anderson Cancer Center, Houston, TX

||||Children's Oncology Group, Philadelphia, PA

***Cincinnati Children's Hospital, Cincinnati, OH

†††University of Alberta Children's Hospital, Edmonton, Alberta, Canada

‡‡‡IWK Children's Hospital, Halifax, Nova Scotia, Canada

§§§Phoenix Children's Hospital, Phoenix, AZ

¶¶¶Children National Medical Center, Washington, DC.

Reprints: Peter Ehrlich, MD, MSC, University of Michigian, Ann Arbor, MI, 48104. E-mail:

This project was supported by grants CA98543 (Children's Oncology Group Chair's grant) and CA98413 (COG SDC grant) from the National Institutes of Health. U10CA180899.

MLR, JSD are co-senior authors.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

The authors report no conflicts of interest.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.